Trial Profile
Phase II study of oxaliplatin and taxotere [docetaxel] in metastatic bladder cancer.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Docetaxel (Primary) ; Oxaliplatin (Primary)
- Indications Bladder cancer
- Focus Adverse reactions
- 29 Mar 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 20 Aug 2007 Status changed from recruiting to in progress.
- 29 Oct 2005 New trial record.